Onzetra Xsail is specifically indicated for the acute treatment of migraine with or without aura in adults. It is supplied as a powder for intranasal administration, delivered with the Xsail breath-powered delivery device only. The recommended dose is 22 mg, administered by use of one nosepiece (11 mg) in each nostril. The maximum dose in a 24-hour period should not exceed two doses (44 mg) separated by at least 2 hours (Ref: Vidhya V. FDA Approved Drugs – January 2016. Drug Discovery, 2016, 11(28), 21-22).
Drug discovery journal is an international drug science magazine which broadly valued among medicine, biotechnology and pharmacology, drug discovery scientists for its unique blend of important research papers, case studies, reviews, perspectives and news. Drug discovery journal involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, it will begin the process of drug development prior to clinical trials. One or more of these steps may, but not necessarily, involve computer-aided drug design.
Drug Discovery Journal delivers exciting primary and advanced drug-discovery research from all areas of biology and medicine, from molecular biology to marketing of drugs, including;